查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2143541

GnRH類似物市場：全球市場預測，2026-2032年

GnRH Analogues Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，GnRH 類似物市場將成長至 36.2 億美元，複合年成長率為 6.48%。

主要市場統計數據
基準年 2025 23.3億美元
預計年份：2026年 24.6億美元
預測年份 2032 36.2億美元
複合年成長率 (%) 6.48%

促性腺激素釋放激素類似物：執行摘要及市場背景

促性腺激素釋放激素（GnRH）類似物是一類調節促性腺激素分泌釋放激素（GnRH）路徑的藥物，根據藥物種類、劑量和治療方案的不同，可以抑製或刺激生殖激素的活性。它們廣泛應用於多種臨床情況，包括荷爾蒙敏感性癌症、子宮內膜異位症、子宮肌瘤、不孕症治療方案以及某些兒童內分泌疾病。其臨床價值取決於患者的選擇、治療持續時間、監測以及副作用（如雌激素缺乏症狀、骨質流失和注射相關反應）的處理。

臨床專業化和醫療資源取得正在改變我們治療患者的方式。

治療方法正朝著更專業化的治療路徑、長效製劑的廣泛應用以及與支持性治療更緊密的結合方向發展。在腫瘤學領域，促性腺激素釋放激素（GnRH）類似物在睾固酮依賴性或雌激素依賴性疾病的治療以及某些治療期間的生育力保護策略中繼續發揮至關重要的作用。在生殖醫學領域，其使用與個人化方案、症狀負擔、年齡、骨骼健康風險和患者意願的關聯日益密切。監管要求、保險報銷規則、供應連續性、管理能力和臨床醫生的熟練程度繼續影響著整個醫療保健系統的可及性。

人工智慧（AI）正在改善藥物選擇、監測和證據產生。

人工智慧 (AI) 可透過幫助臨床醫生整合影像、檢測結果、治療史和不利事件訊息，為促性腺激素釋放激素 (GnRH) 類似物療法提供支援。潛在應用包括識別可能受益於特定治療方案的患者、預測用藥依從性挑戰、識別骨骼健康和心血管狀況風險，以及支持個人化監測方案。在研發領域，AI 可協助臨床試驗受試者招募、亞組分析、藥物安全性監測和真實世界數據 (REW) 產生。這些應用需要經過臨床檢驗的模型、代表性的資料集、透明的決策支援、隱私保護和人工監督。 AI 應作為專家判斷的補充，而非替代。

區域性見解：在醫療服務取得、適應症和醫療系統能力方面存在差異。

北美以腫瘤學、生殖醫學和內分泌學等專科服務為特色，並高度重視保險報銷、預先批准和成本效益。在拉丁美洲，公共醫療保健的可近性、專科醫生資源、藥品採購和供應連續性因國家而異。歐洲受益於成熟的臨床網路和監管協調，但國家保險報銷和處方政策仍然是重要因素。在中東，一些醫療保健系統提供先進的三級醫療服務，但全部區域獲得專科醫生和轉診途徑的機會各不相同。非洲在診斷、腫瘤學和生育基礎設施、藥品採購和治療連續性方面面臨許多限制。亞太地區是一個多元化的環境，高度發展的醫療保健系統與快速成長的專科醫生資源並存，在成本效益、區域指南以及都市區地區的醫療服務可及性方面存在差異。

集團洞察：經濟和體制調整將決定最終實施方案。

東南亞國協在監管成熟度、公共報銷、專科醫生密度以及輔助生殖技術和腫瘤服務的可及性方面存在顯著差異。儘管區域間協調至關重要，但進展不一。金磚國家擁有龐大且多元化的患者群體，但在採購體系、國內生產能力和臨床基礎設施方面卻存在差異。歐盟受益於通用的法律規範，但各國在醫療技術評估和報銷方面的決策仍然影響著醫療服務的可近性。七國集團（G7）的醫療衛生體系通常擁有強大的專科醫生隊伍和完善的藥物安全監測框架，但在成本、人口老化和公平取得醫療服務方面面臨挑戰。海灣合作理事會（GCC）國家的高水準醫療（三級）能力和跨境轉診網路往往較為集中，醫療服務的可及性取決於公共醫療保險覆蓋範圍、外籍人士醫療保健計劃以及採購政策。北約成員國的醫療衛生體系各不相同，但災害防備、藥品供應穩定性和醫療服務的連續性仍是通用的策略挑戰。

各國概況：不同的政策和臨床重點影響醫療服務取得

在澳大利亞，專科醫療服務雖然存在，但各地區的可及性存在差異，也受到公共保險報銷政策的影響。巴西擁有完善的公共和私人醫療體系，但在專科醫生和藥品的可及性方面存在顯著的地區差異。在加拿大，醫療服務的可近性受省級報銷制度、轉診途徑和地理距離的影響。中國在發展專科醫療服務的同時，也努力平衡全國的醫療資源採購、區域可近性和監管要求。法國、德國、義大利和西班牙已在歐洲建立了通用的臨床基礎設施，但每個國家都有自己的報銷制度、處方制度和醫院服務體系。印度的醫療體系規模龐大且多元化，擁有先進的都市區醫療服務，但也面臨成本效益和可近性方面的挑戰。日本和韓國擁有完善的臨床體系，各自擁有獨立的報銷制度、監管規定和人口結構因素。在墨西哥，公共和私立醫療服務之間以及大都會圈和農村地區之間存在差異。在俄羅斯，醫療服務的可近性受到其集中式醫療體系結構、供給側因素和區域差異的影響。英國依賴以指南為基礎、公共資助的醫療保健路徑，醫療服務的可近性受國家和地方政府委託。雖然美國擁有種類繁多的專科醫療保健系統，但其保險制度的設計、核准要求、治療費用以及醫療保健服務的碎片化都會影響患者獲得醫療服務的機會。

優先考慮患者選擇、治療連續性和實證治療路徑。

產業領導者應根據​​腫瘤學、生殖醫學和內分泌學領域通用的明確臨床需求來制定產品策略，而不是將它們視為單一應用案例。加強關於耐受性比較、骨骼健康管理、生育結果、用藥依從性和長期患者報告結局等方面的證據，有助於做出更明智的臨床決策。可靠的供應計劃、按需溫控功能、管理培訓和患者支援服務可以提高治療的連續性。與臨床醫生和醫療保健系統的夥伴關係應側重於教育，以確保合理使用、公平獲取和可互通的監測。對人工智慧的投資應從經過檢驗且可審計的工具入手，這些工具能夠解決實際的工作流程問題並維護臨床醫生的課責。產生本地證據並與保險公司合作對於滿足各國特定的報銷和監管要求至關重要。

調查方法：建構和整合有關臨床實踐、政策和醫療保健系統的證據。

本執行摘要採用結構化的定性整合架構對促性腺激素釋放激素（GnRH）類似物進行評估。評估基於治療機制、已確立的臨床應用、病患管理需求、取得途徑、區域醫療保健系統特徵以及機構分類等因素對證據進行整理。區域、機構分類和國家說明採用比較而非量化方法，旨在突出監管、報銷、專家能力、採購和護理連續性方面的差異。關於人工智慧的討論是基於已記錄的醫療保健應用和實施安全措施。本摘要未使用任何市場規模估算、市場規模、市場佔有率、預測或公司特定聲明。

結論：永續價值取決於準確性、可近性和負責任的創新。

由於促性腺激素釋放激素（GnRH）類似物能夠在多個高需求專科領域可控地調節生殖激素通路，因此它們在臨床上仍然佔據著重要的地位。其未來的價值更取決於精準的患者篩選、與支持性治療的整合、治療依從性、公平的獲取途徑以及穩健的醫療服務體系，而非藥理學本身。雖然需要根據地區和國家差異進行在地化實施，但經過適當檢驗和管理的負責任的人工智慧可以加強監測和證據產生。那些能夠將臨床結果與患者體驗、系統效率和供應連續性聯繫起來的領導者，將更有利於支持永續使用。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 GnRH 類似物市場：依產品類型分類

  • 促效劑
    • 戈舍瑞林
    • 組氨肽
    • Leuprorelin acetate
    • 曲普瑞林
  • 反派
    • 塞托雷克斯
    • 德加雷利克斯
    • 加尼瑞克斯

第8章：GnRH類似物市場：依適應症分類

  • 子宮內膜異位症
  • 性早熟
  • 攝護腺癌
  • 子宮肌瘤

第9章：GnRH類似物市場：以劑型分類

  • 肌肉內注射
  • 鼻噴霧
  • 皮下注射

第10章：GnRH類似物市場：依分銷管道分類

  • 診所
  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章：GnRH類似物市場：依最終用戶分類

  • 居家照護
  • 醫院
  • 專科診所

第12章 GnRH 類似物市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 GnRH 類似物市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 GnRH 類似物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • AbbVie Inc
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Cipla Limited
  • Eisai Co Ltd
  • Endo International plc
  • Ferring Pharmaceuticals SA
  • Gland Pharma Limited
  • Hikma Pharmaceuticals PLC
  • Intas Pharmaceuticals Ltd
  • Ipsen SA
  • Lupin Limited
  • Merck KGaA
  • Novartis AG
  • Organon & Co
  • Pfizer Inc
  • Sanofi SA
  • Sumitomo Pharma Co Ltd
  • Sun Pharmaceutical Industries Ltd
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd
  • Viatris Inc
  • Zydus Lifesciences Limited

第17章 主要專家

Product Code: MRR-9C4233EE7D35

The GnRH Analogues Market is projected to grow by USD 3.62 billion at a CAGR of 6.48% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.33 billion
Estimated Year [2026] USD 2.46 billion
Forecast Year [2032] USD 3.62 billion
CAGR (%) 6.48%

GnRH Analogues: Executive Summary and Market Context

GnRH analogues are medicines that modulate gonadotropin-releasing hormone pathways, producing suppression or stimulation of reproductive hormone activity depending on the agent, dose, and treatment schedule. They are used across clinically distinct settings, including hormone-sensitive cancers, endometriosis, uterine fibroids, infertility protocols, and selected pediatric endocrine disorders. Clinical value depends on appropriate patient selection, treatment duration, monitoring, and management of adverse effects such as hypoestrogenic symptoms, bone loss, and injection-related reactions.

Clinical Specialization and Access Are Reshaping the Landscape

The landscape is shifting toward more specialized treatment pathways, broader use of long-acting formulations, and stronger integration of supportive care. In oncology, GnRH analogues remain relevant to androgen- or estrogen-dependent disease management and to fertility-preservation strategies during selected treatments. In reproductive health, use is increasingly connected with individualized protocols, symptom burden, age, bone-health risk, and patient preferences. Regulatory requirements, reimbursement rules, supply continuity, administration capacity, and clinician familiarity continue to influence access across health systems.

Artificial Intelligence Is Improving Selection, Monitoring, and Evidence Generation

Artificial intelligence can support GnRH analogue care by helping clinicians synthesize imaging, laboratory results, treatment history, and adverse-event information. Potential applications include identifying patients who may benefit from specific treatment pathways, predicting adherence challenges, flagging risks to bone health or cardiovascular status, and supporting individualized monitoring schedules. In research and development, AI can assist trial recruitment, subgroup analysis, pharmacovigilance, and real-world evidence generation. These applications require clinically validated models, representative datasets, transparent decision support, privacy safeguards, and human oversight; AI should complement rather than replace specialist judgment.

Regional Insights: Access, Indication Mix, and Health-System Capacity Differ

North America is characterized by specialized oncology, reproductive, and endocrine services, alongside attention to reimbursement, prior authorization, and treatment affordability. Latin America shows variation in public-sector access, specialist availability, procurement, and continuity of supply across countries. Europe benefits from established clinical networks and regulatory coordination, while national reimbursement and prescribing policies remain important. The Middle East combines advanced tertiary services in some systems with uneven specialist access and referral pathways across the region. Africa faces constraints involving diagnostics, oncology and fertility infrastructure, medicine procurement, and treatment continuity. Asia-Pacific presents a diverse environment spanning highly developed health systems and rapidly expanding specialist capacity, with differences in affordability, local guidelines, and urban-rural access.

Group Insights: Economic and Institutional Coordination Shapes Adoption

ASEAN markets differ substantially in regulatory maturity, public reimbursement, specialist density, and access to assisted reproduction and oncology services, making regional coordination valuable but uneven. BRICS countries combine large and diverse patient populations with differing procurement systems, domestic manufacturing capabilities, and clinical infrastructure. The European Union benefits from shared regulatory structures while national health-technology assessment and reimbursement decisions continue to determine availability. G7 health systems generally have strong specialist capacity and pharmacovigilance frameworks, but face cost, aging-population, and equitable-access considerations. GCC countries often have concentrated tertiary-care capabilities and cross-border referral networks, with access influenced by public coverage, expatriate healthcare arrangements, and procurement policies. NATO members span varied health systems, yet preparedness, medicine resilience, and continuity of care remain common strategic concerns.

Country Insights: Diverse Policies and Clinical Priorities Define Access

Australia combines specialist healthcare with geographically uneven access and public reimbursement considerations. Brazil has substantial public and private healthcare capacity but notable regional differences in specialist availability and procurement. Canada's access is shaped by provincial reimbursement, referral pathways, and geographic distance. China is expanding specialty care while balancing national procurement, local access, and regulatory requirements. France, Germany, Italy, and Spain have established European clinical infrastructures, with country-specific reimbursement, prescribing, and hospital-delivery arrangements. India's large and diverse healthcare system includes advanced urban services alongside affordability and access challenges. Japan and South Korea have sophisticated clinical systems with distinctive reimbursement, regulatory, and demographic considerations. Mexico shows variation between public and private services and between metropolitan and rural settings. Russia's access is influenced by centralized health-system structures, supply considerations, and regional disparities. The United Kingdom relies on guideline-led and publicly funded pathways, with access shaped by national and local commissioning. The United States has broad specialist capability, but insurance design, authorization requirements, treatment costs, and care fragmentation can affect patient access.

Prioritize Patient Selection, Continuity, and Evidence-Based Care Pathways

Industry leaders should align product strategy with clearly defined clinical needs across oncology, reproductive medicine, and endocrinology rather than treating these as a single use case. Strengthening evidence on comparative tolerability, bone-health management, fertility outcomes, adherence, and long-term patient-reported outcomes can support better clinical decisions. Reliable supply planning, temperature-control capability where relevant, administration training, and patient-support services can improve treatment continuity. Partnerships with clinicians and health systems should focus on appropriate-use education, equitable access, and interoperable monitoring. AI investments should begin with validated, auditable tools that address practical workflow problems and maintain clinician accountability. Local evidence generation and payer engagement are important for navigating country-specific reimbursement and regulatory requirements.

Methodology: Structured Synthesis of Clinical, Policy, and Health-System Evidence

This executive summary uses a structured, qualitative synthesis framework for GnRH analogues. The assessment organizes evidence by therapeutic mechanism, established clinical applications, patient-management requirements, access conditions, regional health-system characteristics, and institutional groupings. Regional, group, and country narratives are comparative rather than quantitative and are intended to highlight differences in regulation, reimbursement, specialist capacity, procurement, and continuity of care. Artificial-intelligence considerations are framed around documented healthcare applications and implementation safeguards. No market estimates, market sizing, market shares, forecasts, or company-specific claims are used.

Conclusion: Durable Value Depends on Precision, Access, and Responsible Innovation

GnRH analogues remain clinically important because they provide controllable modulation of reproductive hormone pathways across several high-need specialties. Their future value will depend less on pharmacology alone and more on precise patient selection, supportive-care integration, treatment adherence, equitable access, and resilient delivery systems. Regional and country differences require locally grounded implementation, while responsible AI can strengthen monitoring and evidence generation when validated and governed appropriately. Leaders that connect clinical outcomes with patient experience, system efficiency, and continuity of supply will be best positioned to support sustainable use.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. GnRH Analogues Market, by Product Type

  • 7.1. Introduction
  • 7.2. Agonists
    • 7.2.1. Goserelin
    • 7.2.2. Histrelin
    • 7.2.3. Leuprolide
    • 7.2.4. Triptorelin
  • 7.3. Antagonists
    • 7.3.1. Cetrorelix
    • 7.3.2. Degarelix
    • 7.3.3. Ganirelix

8. GnRH Analogues Market, by Indication

  • 8.1. Introduction
  • 8.2. Endometriosis
  • 8.3. Precocious Puberty
  • 8.4. Prostate Cancer
  • 8.5. Uterine Fibroids

9. GnRH Analogues Market, by Dosage Form

  • 9.1. Introduction
  • 9.2. Intramuscular Injection
  • 9.3. Nasal Spray
  • 9.4. Subcutaneous Injection

10. GnRH Analogues Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Clinics
  • 10.3. Hospital Pharmacies
  • 10.4. Online Pharmacies
  • 10.5. Retail Pharmacies

11. GnRH Analogues Market, by End User

  • 11.1. Introduction
  • 11.2. Home Care
  • 11.3. Hospitals
  • 11.4. Specialty Clinics

12. GnRH Analogues Market, by Region

  • 12.1. Introduction
  • 12.2. Asia-Pacific
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Europe
  • 12.6. Middle East
  • 12.7. Africa

13. GnRH Analogues Market, by Group

  • 13.1. Introduction
  • 13.2. ASEAN
  • 13.3. GCC
  • 13.4. European Union
  • 13.5. BRICS
  • 13.6. G7
  • 13.7. NATO

14. GnRH Analogues Market, by Country

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. United Kingdom
  • 14.7. Germany
  • 14.8. France
  • 14.9. Russia
  • 14.10. Italy
  • 14.11. Spain
  • 14.12. China
  • 14.13. India
  • 14.14. Japan
  • 14.15. Australia
  • 14.16. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. Market Concentration Analysis, 2025
    • 15.2.1. Concentration Ratio (CR)
    • 15.2.2. Herfindahl Hirschman Index (HHI)
  • 15.3. Recent Developments & Impact Analysis, 2025
  • 15.4. Product Portfolio Analysis, 2025
  • 15.5. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. AbbVie Inc
  • 16.2. Astellas Pharma Inc
  • 16.3. AstraZeneca Plc
  • 16.4. Bayer AG
  • 16.5. Boehringer Ingelheim International GmbH
  • 16.6. Cipla Limited
  • 16.7. Eisai Co Ltd
  • 16.8. Endo International plc
  • 16.9. Ferring Pharmaceuticals SA
  • 16.10. Gland Pharma Limited
  • 16.11. Hikma Pharmaceuticals PLC
  • 16.12. Intas Pharmaceuticals Ltd
  • 16.13. Ipsen S.A
  • 16.14. Lupin Limited
  • 16.15. Merck KGaA
  • 16.16. Novartis AG
  • 16.17. Organon & Co
  • 16.18. Pfizer Inc
  • 16.19. Sanofi SA
  • 16.20. Sumitomo Pharma Co Ltd
  • 16.21. Sun Pharmaceutical Industries Ltd
  • 16.22. Takeda Pharmaceutical Company Limited
  • 16.23. Teva Pharmaceutical Industries Ltd
  • 16.24. Viatris Inc
  • 16.25. Zydus Lifesciences Limited

17. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global GnRH Analogues Market, Years Considered for the Study
  • FIGURE 2. Global GnRH Analogues Market, Research Design
  • FIGURE 3. Global GnRH Analogues Market, Research Framework
  • FIGURE 4. Global GnRH Analogues Market, Data Triangulation
  • FIGURE 5. Global GnRH Analogues Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global GnRH Analogues Market Size, by Product Type, 2025 vs 2032 (%)
  • FIGURE 7. Global GnRH Analogues Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global GnRH Analogues Market Size, by Indication, 2025 vs 2032 (%)
  • FIGURE 9. Global GnRH Analogues Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global GnRH Analogues Market Size, by Dosage Form, 2025 vs 2032 (%)
  • FIGURE 11. Global GnRH Analogues Market Size, by Dosage Form, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global GnRH Analogues Market Size, by Distribution Channel, 2025 vs 2032 (%)
  • FIGURE 13. Global GnRH Analogues Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global GnRH Analogues Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 15. Global GnRH Analogues Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global GnRH Analogues Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 17. Global GnRH Analogues Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global GnRH Analogues Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 19. Global GnRH Analogues Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 20. Global GnRH Analogues Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 21. Global GnRH Analogues Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global GnRH Analogues Market Segmentation & Coverage
  • TABLE 2. Global GnRH Analogues Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global GnRH Analogues Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 4. Global Agonists Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Agonists Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Agonists Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Goserelin Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Goserelin Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Goserelin Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Histrelin Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Histrelin Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Histrelin Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Leuprolide Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global Leuprolide Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global Leuprolide Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global Triptorelin Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 17. Global Triptorelin Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 18. Global Triptorelin Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 19. Global Antagonists Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 20. Global Antagonists Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 21. Global Antagonists Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 22. Global Cetrorelix Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 23. Global Cetrorelix Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 24. Global Cetrorelix Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 25. Global Degarelix Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 26. Global Degarelix Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 27. Global Degarelix Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 28. Global Ganirelix Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 29. Global Ganirelix Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 30. Global Ganirelix Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 31. Global GnRH Analogues Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 32. Global Endometriosis Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 33. Global Endometriosis Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 34. Global Endometriosis Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 35. Global Precocious Puberty Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 36. Global Precocious Puberty Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 37. Global Precocious Puberty Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 38. Global Prostate Cancer Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 39. Global Prostate Cancer Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 40. Global Prostate Cancer Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 41. Global Uterine Fibroids Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 42. Global Uterine Fibroids Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 43. Global Uterine Fibroids Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 44. Global GnRH Analogues Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 45. Global Intramuscular Injection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 46. Global Intramuscular Injection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 47. Global Intramuscular Injection Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 48. Global Nasal Spray Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 49. Global Nasal Spray Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 50. Global Nasal Spray Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 51. Global Subcutaneous Injection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 52. Global Subcutaneous Injection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 53. Global Subcutaneous Injection Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 54. Global GnRH Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 55. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 56. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 57. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 58. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 59. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 60. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 61. Global Online Pharmacies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 62. Global Online Pharmacies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 63. Global Online Pharmacies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 64. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 65. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 66. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 67. Global GnRH Analogues Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 68. Global Home Care Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 69. Global Home Care Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 70. Global Home Care Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 71. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 72. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 73. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 74. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 75. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 76. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 77. Global GnRH Analogues Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 78. Asia-Pacific GnRH Analogues Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 79. Asia-Pacific GnRH Analogues Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 80. Asia-Pacific GnRH Analogues Market Size, by Agonists, 2017-2032 (USD Million)
  • TABLE 81. Asia-Pacific GnRH Analogues Market Size, by Antagonists, 2017-2032 (USD Million)
  • TABLE 82. Asia-Pacific GnRH Analogues Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 83. Asia-Pacific GnRH Analogues Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 84. Asia-Pacific GnRH Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 85. Asia-Pacific GnRH Analogues Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 86. North America GnRH Analogues Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 87. North America GnRH Analogues Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 88. North America GnRH Analogues Market Size, by Agonists, 2017-2032 (USD Million)
  • TABLE 89. North America GnRH Analogues Market Size, by Antagonists, 2017-2032 (USD Million)
  • TABLE 90. North America GnRH Analogues Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 91. North America GnRH Analogues Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 92. North America GnRH Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 93. North America GnRH Analogues Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 94. Latin America GnRH Analogues Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 95. Latin America GnRH Analogues Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 96. Latin America GnRH Analogues Market Size, by Agonists, 2017-2032 (USD Million)
  • TABLE 97. Latin America GnRH Analogues Market Size, by Antagonists, 2017-2032 (USD Million)
  • TABLE 98. Latin America GnRH Analogues Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 99. Latin America GnRH Analogues Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 100. Latin America GnRH Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 101. Latin America GnRH Analogues Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 102. Europe GnRH Analogues Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 103. Europe GnRH Analogues Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 104. Europe GnRH Analogues Market Size, by Agonists, 2017-2032 (USD Million)
  • TABLE 105. Europe GnRH Analogues Market Size, by Antagonists, 2017-2032 (USD Million)
  • TABLE 106. Europe GnRH Analogues Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 107. Europe GnRH Analogues Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 108. Europe GnRH Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 109. Europe GnRH Analogues Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 110. Middle East GnRH Analogues Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 111. Middle East GnRH Analogues Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 112. Middle East GnRH Analogues Market Size, by Agonists, 2017-2032 (USD Million)
  • TABLE 113. Middle East GnRH Analogues Market Size, by Antagonists, 2017-2032 (USD Million)
  • TABLE 114. Middle East GnRH Analogues Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 115. Middle East GnRH Analogues Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 116. Middle East GnRH Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 117. Middle East GnRH Analogues Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 118. Africa GnRH Analogues Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 119. Africa GnRH Analogues Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 120. Africa GnRH Analogues Market Size, by Agonists, 2017-2032 (USD Million)
  • TABLE 121. Africa GnRH Analogues Market Size, by Antagonists, 2017-2032 (USD Million)
  • TABLE 122. Africa GnRH Analogues Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 123. Africa GnRH Analogues Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 124. Africa GnRH Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 125. Africa GnRH Analogues Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 126. Global GnRH Analogues Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 127. ASEAN GnRH Analogues Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 128. ASEAN GnRH Analogues Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 129. ASEAN GnRH Analogues Market Size, by Agonists, 2017-2032 (USD Million)
  • TABLE 130. ASEAN GnRH Analogues Market Size, by Antagonists, 2017-2032 (USD Million)
  • TABLE 131. ASEAN GnRH Analogues Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 132. ASEAN GnRH Analogues Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 133. ASEAN GnRH Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 134. ASEAN GnRH Analogues Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 135. GCC GnRH Analogues Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 136. GCC GnRH Analogues Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 137. GCC GnRH Analogues Market Size, by Agonists, 2017-2032 (USD Million)
  • TABLE 138. GCC GnRH Analogues Market Size, by Antagonists, 2017-2032 (USD Million)
  • TABLE 139. GCC GnRH Analogues Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 140. GCC GnRH Analogues Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 141. GCC GnRH Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 142. GCC GnRH Analogues Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 143. European Union GnRH Analogues Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 144. European Union GnRH Analogues Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 145. European Union GnRH Analogues Market Size, by Agonists, 2017-2032 (USD Million)
  • TABLE 146. European Union GnRH Analogues Market Size, by Antagonists, 2017-2032 (USD Million)
  • TABLE 147. European Union GnRH Analogues Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 148. European Union GnRH Analogues Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 149. European Union GnRH Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 150. European Union GnRH Analogues Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 151. BRICS GnRH Analogues Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 152. BRICS GnRH Analogues Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 153. BRICS GnRH Analogues Market Size, by Agonists, 2017-2032 (USD Million)
  • TABLE 154. BRICS GnRH Analogues Market Size, by Antagonists, 2017-2032 (USD Million)
  • TABLE 155. BRICS GnRH Analogues Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 156. BRICS GnRH Analogues Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 157. BRICS GnRH Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 158. BRICS GnRH Analogues Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 159. G7 GnRH Analogues Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 160. G7 GnRH Analogues Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 161. G7 GnRH Analogues Market Size, by Agonists, 2017-2032 (USD Million)
  • TABLE 162. G7 GnRH Analogues Market Size, by Antagonists, 2017-2032 (USD Million)
  • TABLE 163. G7 GnRH Analogues Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 164. G7 GnRH Analogues Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 165. G7 GnRH Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 166. G7 GnRH Analogues Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 167. NATO GnRH Analogues Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 168. NATO GnRH Analogues Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 169. NATO GnRH Analogues Market Size, by Agonists, 2017-2032 (USD Million)
  • TABLE 170. NATO GnRH Analogues Market Size, by Antagonists, 2017-2032 (USD Million)
  • TABLE 171. NATO GnRH Analogues Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 172. NATO GnRH Analogues Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 173. NATO GnRH Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 174. NATO GnRH Analogues Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 175. Global GnRH Analogues Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 176. United States GnRH Analogues Market Size, 2017-2032 (USD Million)
  • TABLE 177. United States GnRH Analogues Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 178. United States GnRH Analogues Market Size, by Agonists, 2017-2032 (USD Million)
  • TABLE 179. United States GnRH Analogues Market Size, by Antagonists, 2017-2032 (USD Million)
  • TABLE 180. United States GnRH Analogues Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 181. United States GnRH Analogues Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 182. United States GnRH Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 183. United States GnRH Analogues Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 184. Canada GnRH Analogues Market Size, 2017-2032 (USD Million)
  • TABLE 185. Canada GnRH Analogues Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 186. Canada GnRH Analogues Market Size, by Agonists, 2017-2032 (USD Million)
  • TABLE 187. Canada GnRH Analogues Market Size, by Antagonists, 2017-2032 (USD Million)
  • TABLE 188. Canada GnRH Analogues Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 189. Canada GnRH Analogues Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 190. Canada GnRH Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 191. Canada GnRH Analogues Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 192. Mexico GnRH Analogues Market Size, 2017-2032 (USD Million)
  • TABLE 193. Mexico GnRH Analogues Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 194. Mexico GnRH Analogues Market Size, by Agonists, 2017-2032 (USD Million)
  • TABLE 195. Mexico GnRH Analogues Market Size, by Antagonists, 2017-2032 (USD Million)
  • TABLE 196. Mexico GnRH Analogues Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 197. Mexico GnRH Analogues Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 198. Mexico GnRH Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 199. Mexico GnRH Analogues Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 200. Brazil GnRH Analogues Market Size, 2017-2032 (USD Million)
  • TABLE 201. Brazil GnRH Analogues Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 202. Brazil GnRH Analogues Market Size, by Agonists, 2017-2032 (USD Million)
  • TABLE 203. Brazil GnRH Analogues Market Size, by Antagonists, 2017-2032 (USD Million)
  • TABLE 204. Brazil GnRH Analogues Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 205. Brazil GnRH Analogues Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 206. Brazil GnRH Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 207. Brazil GnRH Analogues Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 208. United Kingdom GnRH Analogues Market Size, 2017-2032 (USD Million)
  • TABLE 209. United Kingdom GnRH Analogues Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 210. United Kingdom GnRH Analogues Market Size, by Agonists, 2017-2032 (USD Million)
  • TABLE 211. United Kingdom GnRH Analogues Market Size, by Antagonists, 2017-2032 (USD Million)
  • TABLE 212. United Kingdom GnRH Analogues Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 213. United Kingdom GnRH Analogues Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 214. United Kingdom GnRH Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 215. United Kingdom GnRH Analogues Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 216. Germany GnRH Analogues Market Size, 2017-2032 (USD Million)
  • TABLE 217. Germany GnRH Analogues Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 218. Germany GnRH Analogues Market Size, by Agonists, 2017-2032 (USD Million)
  • TABLE 219. Germany GnRH Analogues Market Size, by Antagonists, 2017-2032 (USD Million)
  • TABLE 220. Germany GnRH Analogues Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 221. Germany GnRH Analogues Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 222. Germany GnRH Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 223. Germany GnRH Analogues Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 224. France GnRH Analogues Market Size, 2017-2032 (USD Million)
  • TABLE 225. France GnRH Analogues Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 226. France GnRH Analogues Market Size, by Agonists, 2017-2032 (USD Million)
  • TABLE 227. France GnRH Analogues Market Size, by Antagonists, 2017-2032 (USD Million)
  • TABLE 228. France GnRH Analogues Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 229. France GnRH Analogues Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 230. France GnRH Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 231. France GnRH Analogues Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 232. Russia GnRH Analogues Market Size, 2017-2032 (USD Million)
  • TABLE 233. Russia GnRH Analogues Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 234. Russia GnRH Analogues Market Size, by Agonists, 2017-2032 (USD Million)
  • TABLE 235. Russia GnRH Analogues Market Size, by Antagonists, 2017-2032 (USD Million)
  • TABLE 236. Russia GnRH Analogues Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 237. Russia GnRH Analogues Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 238. Russia GnRH Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 239. Russia GnRH Analogues Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 240. Italy GnRH Analogues Market Size, 2017-2032 (USD Million)
  • TABLE 241. Italy GnRH Analogues Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 242. Italy GnRH Analogues Market Size, by Agonists, 2017-2032 (USD Million)
  • TABLE 243. Italy GnRH Analogues Market Size, by Antagonists, 2017-2032 (USD Million)
  • TABLE 244. Italy GnRH Analogues Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 245. Italy GnRH Analogues Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 246. Italy GnRH Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 247. Italy GnRH Analogues Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 248. Spain GnRH Analogues Market Size, 2017-2032 (USD Million)
  • TABLE 249. Spain GnRH Analogues Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 250. Spain GnRH Analogues Market Size, by Agonists, 2017-2032 (USD Million)
  • TABLE 251. Spain GnRH Analogues Market Size, by Antagonists, 2017-2032 (USD Million)
  • TABLE 252. Spain GnRH Analogues Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 253. Spain GnRH Analogues Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 254. Spain GnRH Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 255. Spain GnRH Analogues Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 256. China GnRH Analogues Market Size, 2017-2032 (USD Million)
  • TABLE 257. China GnRH Analogues Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 258. China GnRH Analogues Market Size, by Agonists, 2017-2032 (USD Million)
  • TABLE 259. China GnRH Analogues Market Size, by Antagonists, 2017-2032 (USD Million)
  • TABLE 260. China GnRH Analogues Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 261. China GnRH Analogues Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 262. China GnRH Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 263. China GnRH Analogues Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 264. India GnRH Analogues Market Size, 2017-2032 (USD Million)
  • TABLE 265. India GnRH Analogues Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 266. India GnRH Analogues Market Size, by Agonists, 2017-2032 (USD Million)
  • TABLE 267. India GnRH Analogues Market Size, by Antagonists, 2017-2032 (USD Million)
  • TABLE 268. India GnRH Analogues Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 269. India GnRH Analogues Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 270. India GnRH Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 271. India GnRH Analogues Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 272. Japan GnRH Analogues Market Size, 2017-2032 (USD Million)
  • TABLE 273. Japan GnRH Analogues Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 274. Japan GnRH Analogues Market Size, by Agonists, 2017-2032 (USD Million)
  • TABLE 275. Japan GnRH Analogues Market Size, by Antagonists, 2017-2032 (USD Million)
  • TABLE 276. Japan GnRH Analogues Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 277. Japan GnRH Analogues Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 278. Japan GnRH Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 279. Japan GnRH Analogues Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 280. Australia GnRH Analogues Market Size, 2017-2032 (USD Million)
  • TABLE 281. Australia GnRH Analogues Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 282. Australia GnRH Analogues Market Size, by Agonists, 2017-2032 (USD Million)
  • TABLE 283. Australia GnRH Analogues Market Size, by Antagonists, 2017-2032 (USD Million)
  • TABLE 284. Australia GnRH Analogues Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 285. Australia GnRH Analogues Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 286. Australia GnRH Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 287. Australia GnRH Analogues Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 288. South Korea GnRH Analogues Market Size, 2017-2032 (USD Million)
  • TABLE 289. South Korea GnRH Analogues Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 290. South Korea GnRH Analogues Market Size, by Agonists, 2017-2032 (USD Million)
  • TABLE 291. South Korea GnRH Analogues Market Size, by Antagonists, 2017-2032 (USD Million)
  • TABLE 292. South Korea GnRH Analogues Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 293. South Korea GnRH Analogues Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 294. South Korea GnRH Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 295. South Korea GnRH Analogues Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 296. Global GnRH Analogues Market Share, by Key Player, 2025
  • TABLE 297. Global GnRH Analogues Market, Key Experts